Comparison with antibody-based radiolabeled EGFR imaging probes, which were tested using the same A431 xenograft model, shows that the tumor uptake of [123I]I-(HE)3-E01-PIB at 4 h after injection (1.29 ± 0.36%ID/g) was lower than the peak uptake of 89Zr-labeled cetuximab (~4%ID/g at 96 h after injection [17] or 86Y-labeled panitumumab (22.74 ± 1.7%ID/g) [56]. This evidence concerns the gene EGFR and neoplasm.